Non-transplant salvage therapy for low-risk relapsed/refractory pediatric classical Hodgkin lymphoma (cHL) had high rates of progression-free (PFS) and overall survival (OS) at 3-5 years ...

And for many people with these cancers, like Laura, relapse scenarios are all too familiar. But treatment options for NHL are on the rise. Rising rates of non-Hodgkin's lymphoma in the U.S. are ...

Patients with relapsed and refractory HL have an increased chance of cure with HDT and ASCT, which can be estimated at approximately 50-60%. All outcomes are better in late relapses and if ...

Hodgkin's lymphoma is a type of cancer that affects the lymphatic system, which is part of the body's immune system that fights disease and germs. "Yesterday I was informed that I have relapsed ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Cancer Center have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient's likely response ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

Non-Hodgkin’s lymphoma (NHL) has several subtypes with ... about a person’s outlook and life expectancy, their chance of relapse, and more. NHL is a group of blood cancers that have similar ...

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...

In 1997, rituximab received approval for use by the United States Food and Drug Administration (US FDA) for the treatment of patients with relapsed low-grade non-Hodgkin lymphomas. It was the ...

Azercabtagene zapreleucel has been granted fast track designation from the FDA for the treatment of diffuse large B-cell ...